The EU said J&J's planned sale of its trauma business would ensure the combined companies would continue to face competition and leave enough alternatives for doctors and patients.
Synthes is J&J's largest acquisition to date. U.S. regulators have not yet approved the deal.
J&J offered to buy Synthes in April 2011 for 159 Swiss francs a share in cash and stock. It plans to sell its global trauma business to Biomet for $280 million in cash.
Ford (F) is trending as the automaker is planning a new $760 million assembly plant in China that is expected to double its output in the country. Construction on the plant will start later this year and should open in 2015. Though it will initially produce 250,000 vehicles a year, Ford expects the plant to eventually double its production to 1.2 million vehicles annually. The factory makes Ford's total investment in China now $4.9 billion. The company plans to bring 15 new models and 20 new engines and transmissions to the country by 2015.
Human Genome Sciences (HGSI) is another popular topic after rejecting an unsolicited $2.6 billion bid from GlaxoSmithKline (GSK). Human Genome said the $13-a-share cash offer "does not reflect the value inherent" in the company. Human Genome said its board has authorized exploring strategic alternatives, include a possible sale of the company, and GlaxoSmithKline has been invited to participate in the process. The two companies are partners on lupus treatment Benlysta, which was approved by U.S. and European regulators last year. The companies are also collaborating on two other experimental drugs.
The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move. -- Written by Brittany Umar.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV